The AlphaLISA® human PD-1/PD-L2 binding kit is designed for the detection of binding activity between human PD-1 and PD-L2, using a fast and simple homogeneous AlphaLISA assay (no wash steps). This assay can be used to screen for small molecules that inhibit binding, as a competitive ligand binding (CLB) assay to screen therapeutic blocking antibodies, and for potency assays.
false falseFor research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
This kit is designed for the detection of binding activity between PD-1 and PD-2 using a homogeneous AlphaLISA assay (no wash steps). This assay can facilitate the design and development of therapetics by using competitive binding.
Features:
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a biotinylated PD-1 binds to the Streptavidin-coated Alpha Donor beads, while His tagged PD-L2 is captured by Anti-His AlphaLISA Acceptor beads. When PD-L2 binding to PD-1 happens, Donor beads and Acceptor beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Programmed Cell Death 1 Ligand 2 (PD-L2), also known as cluster of differentiation 273 (CD273) or B7-DC, is one of 2 ligands that binds to programmed death 1 (PD-1), the other being programmed cell death ligand 1 (PD-L1). These two ligands are members of the B7 superfamily that provide signals for regulating T-cell activation and tolerance. PD-L2 is expressed on a subset of dendritic cells, memory B cells, and monocytes in tissues, where its highest expression has been proven to be on the liver, heart, placenta, spleen, pancreas, and lymph node. The binding of PD-L2 and PD-1 promotes IFN-gamma production and CD40 ligand up-regulation while inhibiting IL-4 production.
檢測目標 | PD-1, PD-L1 |
---|---|
檢測目標類 | Protein |
檢測技術 | Alpha |
自動化兼容 | Yes |
檢測方法 | Alpha |
實驗類型 | In vitro |
產品品牌名稱 | AlphaLISA |
運輸條件 | 藍冰 |
治療領域 | Immuno-oncology |
產品尺寸 | 5,000 assays points |
Chimeric antigen receptor (CAR) T-cell therapy has transformed the field of immuno-oncology providing a novel approach to treating certain blood cancers. As innovation progresses with the design of next-generation chimeric receptors and a better understanding of the tumor microenvironment, CAR-T ...